Angelica keiskei extract improves insulin resistance and hypertriglyceridemia in rats fed a high-fructose drink.
Angelica keiskei is a traditional herb peculiar to Japan and abundantly contains vitamins, dietary fiber and such polyphenols as chalcone. We investigated in the present study the effect of A. keiskei on insulin resistance and hypertriglyceridemia in fructose-drinking rats as a model for the metabolic syndrome. Male Wistar rats were given a 15% fructose solution as drinking water for 11 weeks. Fructose significantly increased the levels of serum insulin and triglyceride (TG) compared with the control level. Treatment with an ethanol extract of A. keiskei (AE) significantly reduced the levels of blood glucose (-16.5%), serum insulin (-47.3%), HOMA-R (-56.4%) and TG (-24.2%). A hepatic gene analysis showed that fructose reduced the expression of the genes related to fatty acid β-oxidation and high-density lipoprotein (HDL) production. Treatment with AE enhanced the expression of the acyl-CoA oxidase 1 (ACO1), medium-chain acyl-CoA dehydrogenase (MCAD), ATP-binding membrane cassette transporter A1 (ABCA1) and apolipoprotein A1 (Apo-A1) genes. These results suggest that AE improved the insulin resistance and hypertriglyceridemia of the fructose-drinking rats.
Department of Molecular Gastroenterology and Hepatology, Kyoto Prefectural University of Medicine, Japan. onogih@takara-bio.co.jp
Hiromu
H
Ohnogi
Shoko
S
Hayami
Yoko
Y
Kudo
Suzu
S
Deguchi
Shigetoshi
S
Mizutani
Tatsuji
T
Enoki
Yuko
Y
Tanimura
Wataru
W
Aoi
Yuji
Y
Naito
Ikunoshin
I
Kato
Toshikazu
T
Yoshikawa
D064286:ATP Binding Cassette Transporter 1; D018528:ATP-Binding Cassette Transporters / Q000378:metabolism; D042964:Acyl-CoA Dehydrogenase / Q000378:metabolism; D042962:Acyl-CoA Oxidase / Q000378:metabolism; D029969:Angelica / Q000737:chemistry*; D000818:Animals; D016632:Apolipoprotein A-I / Q000378:metabolism; D001786:Blood Glucose / Q000032:analysis; D060766:Drinking Water / Q000008:administration & dosage; D005632:Fructose / Q000008:administration & dosage; D015870:Gene Expression / Q000187:drug effects; D015228:Hypertriglyceridemia / Q000097:blood / Q000139:chemically induced / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000302:isolation & purification / Q000494:pharmacology*; D007328:Insulin / Q000097:blood; D007333:Insulin Resistance; D008075:Lipoproteins, HDL / Q000097:blood; D008099:Liver / Q000187:drug effects / Q000378:metabolism; D008297:Male; D024821:Metabolic Syndrome / Q000097:blood / Q000139:chemically induced / Q000188:drug therapy*; D010936:Plant Extracts / Q000737:chemistry / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar; D014280:Triglycerides / Q000097:blood
D064286:ATP Binding Cassette Transporter 1; D018528:ATP-Binding Cassette Transporters; D016632:Apolipoprotein A-I; D001786:Blood Glucose; D060766:Drinking Water; D000960:Hypolipidemic Agents; D007328:Insulin; D008075:Lipoproteins, HDL; D010936:Plant Extracts; D014280:Triglycerides; D005632:Fructose; D042962:Acyl-CoA Oxidase; D042964:Acyl-CoA Dehydrogenase